SUMMARY
Very low energy diets (VLED) appear to be the most efficacious dietarybased obesity reduction treatments in obstructive sleep apnea (OSA); however, effective weight loss maintenance strategies remain untested in this condition. Our study aimed to assess the feasibility, tolerability and efficacy of two common maintenance diets during a 10-month follow-up period after rapid weight loss using a 2-month VLED. In this two-arm, single-centre, open-label pilot trial, obese adult OSA patients received a 2-month VLED before being allocated to either the Australian Guide to Healthy Eating diet (AGHE) or a low glycaemic index high-protein diet (LGHP). Outcomes were measured at 0, 2 and 12 months. We recruited 44 patients [113.1 AE 19.5 kg, body mass index (BMI): 37.2 AE 5.6 kg m À2 , 49.3 AE 9.2 years, 12 females]. Twenty-four patients were on continuous positive airway pressure (CPAP) or mandibular advancement splint (MAS) therapy for OSA. Forty-two patients completed the VLED. The primary outcome of waist circumference was reduced by 10.6 cm at 2 months [95% confidence interval (CI): 9.2-12.1], and patients lost 12.9 kg in total weight (95% CI: 11.2-14.6). There were small but statistically significant regains in waist circumference between 2 and 12 months [AGHE = 3.5 cm (1.3-5.6) and LGHP = 2.8 cm (0.6-5.0]. Other outcomes followed a similar pattern of change. After weight loss with a 2-month VLED in obese patients with OSA, a structured weight loss maintenance programme incorporating commonly used diets was feasible, tolerable and efficacious for 10 months. This programme may be deployed easily within sleep clinics; however, future research should first test its translation within general clinical practice.
IN TROD UCTI ON
Randomized controlled trials have shown that obesity reduction is effective in reducing obstructive sleep apnea (OSA) severity and improving associated cardiovascular risk factors (Chirinos et al., 2014; Johansson et al., 2009; Kajaste et al., 2004; Kemppainen et al., 2008; Nerfeldt et al., 2008a; Tuomilehto et al., 2009) , making it a viable alternative, given the poor compliance with continuous positive airway pressure (CPAP), which is the gold standard for OSA treatment (Weaver and Grunstein, 2008) . It is well established that use of a very low energy diet (VLED) is an efficacious means of inducing significant and rapid weight reduction in patients with and without OSA (Barnes et al., 2009; Johansson et al., 2009; Kajaste et al., 2004; Larsen et al., 2010; Nerfeldt et al., 2008b; Parretti et al., 2016; Tuomilehto et al., 2009) . However, maintenance of this weight loss is challenging, and obese cohorts typically experience regain after 6 months (Anderson et al., 2001; Franz et al., 2007; Tsai and Wadden, 2006) . Furthermore, the deployment of such intensive weight loss strategies in obesity and speciality clinics poses difficulties, and the translation of this model to real-world settings is not without inherent challenges (Appel et al., 2011; Tsai et al., 2015; Wadden et al., 2013) . Previous randomized controlled trials in patients with OSA using a VLED have not specifically addressed eventual weight regain. The reasons include too short a follow-up period (Chirinos et al., 2014; Kansanen et al., 1998; Nerfeldt et al., 2008a) or lacked implementation of a formal weight loss maintenance programme that included both prescribed diet and exercise to explicitly prevent weight regain (Barnes et al., 2009; Chirinos et al., 2014; Johansson et al., 2011; Kajaste et al., 2004; Kansanen et al., 1998; Nerfeldt et al., 2010) . Of the studies that included a formal weight maintenance programme, the intensive visit schedule precludes their translation to clinical practice due to high patient burden (Johansson et al., 2011; Tuomilehto et al., 2010) . These two studies were also not generalizable, in that they were limited exclusively to either mild or treated OSA. It has been hypothesized that OSA might be obesogenic and could impede weight loss with limited improvements in cardiometabolic health (Borel et al., 2012) . It is therefore important to test whether common dietary prescriptions, when combined with exercise, maintain weight loss and associated benefits in patients with the full range of OSA severity, regardless of treatment.
The primary hypothesis of our study is that weight loss maintenance using two commonly prescribed diets is feasible, tolerable and efficacious in patients with OSA. Following rapid weight loss with a VLED, our primary aim was to maintain the reduction in central obesity (determined by our primary outcome of waist circumference) for 10 months. Given the potential for OSA treatment to modulate weight loss we deliberately included treated and untreated OSA patients in the study. We also aimed to assess OSA and cardiometabolic function and to determine whether sympathetic activity at baseline or following the VLED were associated with the amount of overall weight loss or the degree of weight regain. We chose to test the programme efficacy with two specific maintenance diets used commonly in Australia [the Australian Guide to Healthy Eating (AGHE; Dixon et al., 2012) and the low glycaemic index high-protein diet (LGHP, Larsen et al., 2010) ] to facilitate the translatability of these findings into clinical practice. Importantly, however, it was not an aim of this pilot trial to compare these dietary approaches, because we did not have a hypothesis that these diets are different and we did not have enough patients to test for equivalence.
METHODS

Design
This was a single-centre, open-label trial of 2 months VLED followed by one of two maintenance diets for a further 10 months (AGHE or LGHP). This study was approved by the Sydney Local Health District Research and Ethics Committee (RPAH Zone; HREC/12/RPAH/533); the clinical trial registration number is ACTRN12613000191796. Written informed consent was obtained from all patients.
For the purposes of equal explanatory power we also aimed to recruit equal numbers of patients into two strata defined by whether they did, or did not, use mechanical treatments for their OSA [i.e. CPAP or mandibular advancement devices (MAD)]. Patients were randomized (in a 1 : 1 ratio) to either diet to minimize allocation bias and provide a fair test of whether each maintenance diet was efficacious in patients from the same population. Importantly, we specifically did not intend to compare statistically the efficacy of the two diets but, instead, to provide patients and clinicians with two viable weight loss maintenance options. Patients were excluded if they were involved actively in a structured weight loss programme for the preceding 3 months, had any contraindications to exercise (e.g. known aneurysm, severe aortic stenosis, unstable angina or severe musculoskeletal problems) or if, in the study physician's opinion, they would not be a suitable candidate for a weight loss programme. Patients with a history of liver or renal failure were excluded, as a VLED is contraindicated in such conditions. Patients with a history or presence of eating disorders, significant or extensive food allergies or significant food intolerances were excluded. Those exhibiting uncontrolled medical or psychiatric illness, including unstable diabetes or heart conditions, were also excluded from the study. Patients unwilling to be randomized or take part in the intensive VLED phase of the programme were also excluded.
Study population
Interventions
The interventions were delivered within the infrastructure of an established specialist sleep clinic by a single clinician (first author EAC). The clinician was a university-trained accredited exercise physiologist and nutritionist who had also completed training in health coaching. The intervention consisted of two phases, and both maintenance dietary models were equivalent in the time required for delivery. All patients underwent an intensive weight loss phase involving an 8-week VLED using a standard 450-800-calorie protocol followed by 4 weeks' gradual reintroduction of normal food. During the VLED, patients were permitted to consume a minimum of two cups of low-starch vegetables. At 2 months, patients were allocated to one of two iso-caloric maintenance diets, the AGHE or LGHP.
ª 2017 European Sleep Research Society Patients' energy requirements were calculated using the Harris-Benedict equation and appropriate activity factor (Harris and Benedict, 1918) . A 500-calorie deficit was applied to promote sustained weight loss following completion of the VLED. Both diets used dietary modelling to define portion sizes and 'units' were assigned based on the macronutrient target of each diet (Department of Health and Ageing Australia, 2011: Energy). Nutritional education was also provided where the emphasis of the AGHE diet was on sources of fibre, wholegrains and a focus upon reduced sugar and fat intake. The LGHP diet encouraged patients to obtain as low a glycaemic index as possible while maintaining lean sources of protein and reduced saturated and transfat intake (but not total fat). Exercise was self-managed and targets were set in accordance with the American College of Sports Medicines' position stand on reducing overweight and obesity (250 min cardio per week and two structured resistance training sessions; Donnelly et al., 2009) . All patients undertook a lifestyle modification programme concurrently, with emphasis on health coaching, exercise, food thoughts, lapses and maintenance of change. The clinician responsible for conducting all sessions had training in health coaching (a model that favours acceptance commitment therapy and solution-focused therapy).
Each visit included a 1-2-h individual consultation led by a dual-trained exercise physiologist and nutritionist. Patient contact during the year consisted of three overnight visits (including a 1-h consultation alongside assessments), two clinic visits (lasting approximately 1-2 h) and two telephoneor Skype-based consultations (lasting approximately 20-45 min). In addition, there were three brief telephone calls to confirm appointment scheduling, collect information on side effects and dietary compliance at weeks 1 and 2 of the VLED and at the 9-month time-point. The structure of the programme was designed to fit within the Australian public health-care system, therefore five face-to-face consultations were scheduled to match the access entitlement of patients with a chronic condition. This favoured potential generalizability of the intervention to real-world settings. Further details regarding the interventions and methods are provided in the Data S1.
Outcome measures
The primary outcome was change in waist circumference measured between the iliac crest and the lowest rib, between 2 and 12 months (WHO 2008) . Our initial registered primary outcome was fat mass reduction, as measured by bioimpedance spectroscopy. However, we changed the primary outcome (with the trial registration body) after trial commencement because the measurement was deemed to be unreliable in patients with a BMI >35 kg m À2 undergoing rapid weight loss (Kyle et al., 2004) . No other changes were made to the protocol. Secondary and tertiary outcomes included AHI by inlaboratory polysomnography, general quality of life using the 36-Item Short Form Health Survey (SF-36), anthropometry, blood pressure, the Epworth Sleepiness Scale and pathology-based cardiometabolic risk factors (insulin sensitivity, blood pressure, triglycerides, cholesterol, fasting blood glucose and insulin, glycated haemoglobin, testosterone and sympathetic activity as an effect modifier as measured by 24-h urinary catecholamines adrenaline and noradrenaline and nocturnal heart rate variability). All outcomes were measured at baseline, 2 and 12 months (excluding polysomnography, that was only collected in all patients at baseline and 12 months) and details are provided in the Data S1. Feasibility was assessed by the recruitment rate, physician referrals and willingness to enrol patients and the volume of resources/personnel required to conduct the intervention. Tolerability was assessed by patient retention and compliance with the programme. Efficacy was indicated by the amount of weight loss achieved.
Randomization, allocation concealment and blinding
Randomization was stratified by mechanical treatment status (CPAP or MAD versus none) for the purposes of equal explanatory power within each dietary intervention capped at 24 patients to ensure 20 completers. Randomization lists allocating patients to their weight maintenance diets with random block sizes of 4, 6 and 8 were computer-generated using a 1 : 1 ratio and allocations were enclosed in opaque sealed prenumbered envelopes. Post-randomization blinding of investigators and staff or patients was not possible and was not attempted.
Statistics
There was no formal sample size calculation, as this was a pilot trial. Despite no power calculation, an a priori maximum target of 48 participants was selected. Statistical analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC, USA). Data are presented as mean AE standard deviation or 95% confidence intervals (CI). P-values of <0.05 were considered statistically significant. Point estimate data are described in tables and mean and standard error in figures.
Data were analysed on an intention-to-treat basis for all randomized patients. Mixed-model analyses of variance were used to test the weight maintenance effects within each diet and within each stratum. Time was the fixed effect and individual patients were the random effect. Correlational analyses were performed using Spearman's non-parametric tests.
RESULTS
Feasibility and tolerability
Sufficient physician referrals were received to enable recruitment of 44 patients within 6 months. This rapid referral and ª 2017 European Sleep Research Society recruitment indicated that the intervention was feasible and accepted within clinical practice, and minimal resources were required for delivery. Recruitment occurred between April and October 2013 and was stopped after 6 months, when both the mechanical and non-mechanical treatment strata targets were met. Follow-up was completed by November 2014. Of the 44 enrolled participants, 42 completed the 2-month VLED intervention (see Table 1 ) and were assigned to a weight : n = 18 (AGHE = 9, LGHP = 9) ‡ AHI recorded for patients not using mechical therapy only (AGHE n = 8, and LGHP = 10) § Hypertension defined as systolic blood pressure greater than or equal to 140 mmHg, or diastolic blood pressure greater than or equal to 90 mmHg, or antihypertensive medication prescription ¶ Dyslipidaemia defined as total cholesterol >5.5 mmol L À1 OR triglycerides >1.7 mmol L À1 and/or HDL-c <1.0 mmol L À1 or prescription of a cholesterol lowering medication; Diabetes defined as a diagnosis made by a general practitioner **Testosterone reported in men only (n = 31).
ª 2017 European Sleep Research Society maintenance diet (20 in the AGHE group, 22 in the LGHP group). The intervention was tolerable, as there was a high rate of patient retention: two patients withdrew during the VLED, three patients discontinued the maintenance intervention (two from the LGHP group and one from the AGHE) and one patient in the LGHE group was lost to follow-up (Fig. 1) .
No patients required booster sessions in addition to the scheduled visits. An average of 6.5 h of clinical consultation time was required per patient to deliver the intervention during the course of 12 months.
Efficacy
During the VLED phase patients lost an average of 10.6 cm waist circumference (95% CI: 9.2-12.0) and 12.9 kg in body weight (95% CI: 11.2-14.6) at 2 months. Table 2 describes the effects of the VLED and then the weight maintenance phase for the AGHE diet; Table 3 describes the LGHP diet. Fig. 2 and Supporting information, Fig. S1 plot the waist circumference changes in both groups through the VLED and maintenance phases for each diet and Fig. 3 plots the weight of the patients in the same manner. Supporting information, Table S1 describes the changes in other metabolic outcomes in the two diets throughout the trial. Supporting information, Tables S2 and S3 present the outcome data stratified by whether or not the patients were receiving mechanical therapy at baseline. In patients who were not using mechanical therapies in whom we had sleep studies no patient in either diet group had their sleep apnea cured, as all had an AHI ≥ 5 at 12 months. 
Safety
No serious adverse events (unplanned hospitalizations or death) occurred during the 2-month VLED period. The most common side effect reported during the VLED was constipation, and all patients were recommended to commence a fibre supplement and ensure that water intake was adequate to relieve symptoms. Three serious adverse events occurred during the AGHE and one during the LGHP diets. All were musculoskeletal in nature, including a spinal and wrist fracture. Seven patients in the AGHE group were using antihypertensive medication at the end of the VLED, and this was reduced to six patients at 12 months. In the LGHP group 10 participants were on anti-hypertensive medication at 2 months, and this was reduced to six patients at 12 months. Changes in blood pressure are reported in Supporting information, Table S1 . Sympathetic activity measured by the 24-h This table includes data from only those patients who completed the two-month very low energy diet because its purpose is to show efficacy and weight rebound. Bold text or * indicates p-value < 0.05 and 2-12 month data are the only figures bolded when significant because of the focus on weight rebound. † calculated only for patients not using mechanical treatment (n = 10); AHI: apnea hypopnea index; ODI: oxygen desaturation index; ESS: Epworth sleepiness scale; SF-36: Short Form 36 Questionnaire; The discrepancy between the arithmetic means and the mixed model based delta is due to the statistical methodology used where the mixed model imputes existing data to fill missing data points.
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DI SCUSSION
This weight loss maintenance programme piloting two common diets for our obese OSA patients was feasible, tolerable and efficacious for a period of 10 months. Our attempt to ameliorate weight rebound using two different maintenance diets (AGHE or LGHE diets) was largely successful. By 12 months, patients in our trial had regained approximately 29% of the post-VLED waist circumference and 24% body weight across both diet groups. The small magnitude of waist and weight regain indicated that both of the weight maintenance diets were probably efficacious in preventing full regain to 12 months. In the patients who underwent sleep studies at 12 months (the non-mechanically treated patients) there were clinically meaningful reductions in sleep apnea severity, indicating that weight loss is a long-term viable clinical option for reducing OSA severity; however, weight loss was not curative of sleep apnea in any case. A previously published weight maintenance intervention of similar design to ours in a non-OSA cohort resulted in an arithmetically slightly less weight regain during a shorter period of 6 months (Larsen et al., 2010) . Our 10-month programme provided weight and waist reduction of a magnitude comparable to a previous randomized controlled trial in patients with OSA (Tuomilehto et al., 2009) . That trial recruited participants with only mild OSA with the goal of curing OSA, whereas our study recruited patients with mildto-severe OSA with the goal of testing weight maintenance strategies. The other VLED trial in CPAP-treated OSA patients achieved a remarkable improvement in anthropometry during the 2-month VLED and at 1 year, the open label extension of that trial involving an intensive maintenance phase-observed regain that was similar in magnitude to ours (Johansson et al., 2011) . The intervention used to achieve weight maintenance in that study included monthly 3-h hour face-to-face meetings, which could be a deterrent in terms of cost and resources in many health-care systems. This would ultimately limit the routine use of such a programme in sleep clinics. Our study was designed specifically to be a pragmatic translatable programme in the Australian health-care system and might be modified easily be to fitted into other countries' health systems.
While CPAP treatment remains the first line of therapy for OSA, several studies have shown that short-term CPAP without concurrent weight loss does not reduce visceral abdominal fat (Iftikhar et al., 2014) , and the cardiometabolic effects are, at best, also small in magnitude (Jullian-Desayes et al., 2015) . Moreover, there is evidence suggesting that only 50% of patients can maintain CPAP use (Grote et al., 2000) , and OSA presence may render weight loss programmes less effective (Borel et al., 2012) . A secondary aim was to verify whether the dietary and exercise intervention was effective in both mechanically treated and untreated patients. The VLED and maintenance diets were safe and of minimal risk with a low rate of adverse events, and only a small number of serious events, all occurring during the maintenance phase of the programme. The increase in triglycerides and total cholesterol measured in both groups were of no clinical significance and remained within healthy ranges. As with other weight loss trials in OSA, we were able to reduce the need for antihypertensive medications in some patients by 12 months and, on average, patients remained normotensive following weight loss (Johansson et al., 2011) . Irrespective of OSA treatment, managing physicians should continue to incorporate multi-disciplinary services where effective weight management is pivotal in reducing the burden of obesity and OSA related cardiometabolic dysfunction.
There are a number of limitations to our study. First, we had to change our primary outcome of bio-impedancemeasured fat mass after study commencement. This was due to the greater error associated with bio-impedance spectroscopy in patients with a BMI >35 kg m À2 , especially during times of extreme weight loss that generate greater artefact (Kyle et al., 2004) . Secondly, determination of OSA status with polysomnography could be measured only in patients not using mechanical therapy. As many patients were already established on CPAP, we decided that CPAP withdrawal was not clinically justifiable. Thirdly, our cohort was in relatively good cardiometabolic health despite suffering comorbid OSA and obesity. This lack of metabolic derangement may have limited the potential for health benefit. Fourthly, while our primary aim was to assess the feasibility, tolerability and efficacy of this intervention during weight maintenance, we were unable to determine the overall acceptability of the programme. This would need to be based upon quantifying the numbers of patients who refused to participate in the trial, which we were unable to measure due to competitive recruitment with other concurrent studies. The limited sample size may have reduced the power to detect improvement in some outcomes. However, based on a posthoc power calculation (see Data S1) using our own data, we estimate that we had greater than 80% power to detect the small regain that occurred in the primary outcome of waist circumference. An important study characteristic is that, by using a single clinician (EAC) and single location, we were able to ensure consistency in the setting, measurement techniques and intervention delivery. However, a larger translational trial would need to be delivered in a variety of sites with multiple clinicians to confirm generalizability to a broader OSA population in different national health-care settings. Another weakness is that because we chose active interventions we cannot be sure within this study that either of our interventions reduced weight regain below what would have occurred had we done nothing. In summary, we have shown that weight loss with a VLED diet in obese OSA patients can mainly be maintained for up to 10 months using a dietary and exercise programme that is feasible, tolerable and efficacious. Furthermore, weight maintenance was achieved in patients with a full range of OSA severity, regardless of whether or not they were receiving OSA mechanical treatment. Our study offers a promising translatable programme to alleviate the disease burden of obesity in this male-predominant population.
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